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Carbohydrate Syntrophy 
enhances the establishment of 
Bifidobacterium breve UCC2003 in 
the neonatal gut
Mary O’Connell Motherway1,2, Frances O’Brien1, Tara O’Driscoll1, Patrick G. Casey1, 
Fergus Shanahan1,3 & Douwe van Sinderen1,2
The non-digestible oligosaccharide fraction of maternal milk represents an important of carbohydrate 
and energy source for saccharolytic bifidobacteria in the gastrointestinal tract during early life. 
However, not all neonatal bifidobacteria isolates can directly metabolise the complex sialylated, 
fucosylated, sulphated and/or N-acetylglucosamine-containing oligosaccharide structures present 
in mothers milk. For some bifidobacterial strains, efficient carbohydrate syntrophy or crossfeeding 
is key to their establishment in the gut. In this study, we have adopted advanced functional genomic 
approaches to create single and double in-frame deletions of the N-acetyl glucosamine 6-phosphate 
deacetylase encoding genes, nagA1 and nagA2, of B. breve UCC2003. In vitro phenotypic analysis 
followed by in vivo studies on co-colonisation, mother to infant transmission, and evaluation of 
the relative co-establishment of B. bifidum and B. breve UCC2003 or UCC2003ΔnagA1ΔnagA2 in 
dam-reared neonatal mice demonstrates the importance of crossfeeding on sialic acid, fucose and 
N-acetylglucosamine-containing oligosaccharides for the establishment of B. breve UCC2003 in the 
neonatal gut. Furthermore, transcriptomic analysis of in vivo gene expression shows upregulation of 
genes associated with the utilisation of lactose, sialic acid, GlcNAc-6-S and fucose in B. breve UCC2003, 
while for UCC2003ΔnagA1ΔnagA2 only genes for lactose metabolism were upregulated.
Bifidobacteria are among the earliest and most abundant bacterial colonisers of the neonatal gut where their 
presence is associated with a myriad of benefits to the host intestinal, metabolic and immune health1. While 
the genus Bifidobacterium comprises more than 50 species/subspecies, the dominant infant associated species 
include Bifidobacterium longum subsp. longum, Bifidobacterium longum subsp infantis, Bifidobacterium bifidum, 
Bifidobacterium breve, Bifidobacterium pseudocatenulatum, Bifidobacterium. catenulatum, Bifidobacterium kashi-
wanohense, and Bifidobacterium adolescentis2,3. The dominance of bifidobacteria in breastfed infants has been 
attributed to their ability to utilise human milk oligosaccharides (HMOs). In particular, strains of B. longum 
subsp. infantis and B. bifidum have been studied extensively for their ability to utilise host derived carbohydrates 
and have been found to harbour dedicated, yet distinct, metabolic capabilities for the utilisation of HMOs4,5 
while more recently specific strains of B. longum subsp. longum, B. pseudocatenulatum and B. kashiwanohense 
have been investigated for their ability to utilise fucosyllactose, the dominant oligosaccharide in human milk6,7. 
Intriguingly, the ability to utilise HMOs would seem to be a variable trait among infant-derived strains of B. 
breve, with some strains exhibiting good growth on purified HMOs under in vitro conditions, while other B. breve 
strains exhibit no appreciable growth2. The presence and isolation of B. breve strains that do not directly metab-
olise HMOs would suggest that these strains likely adopt carbohydrate syntrophy to allow their establishment in 
the infant gut. We hypothesise that B. breve, and perhaps other Bifidobacterium sp, can exploit the extracellular 
glycosyl-hydrolase activity of other (bifido)bacterial members of the infant gut microbiome as a source of fer-
mentable carbohydrates to support growth in the intestine.
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We have previously shown that B. breve UCC2003, a nursling infant stool isolate, can efficiently utilise sialic 
acid, but not host derived 3′ sialyllactose, as sole carbohydrate source8. However, B. breve UCC2003 can cross-
feed on released sialic acid derived from the extracellular metabolism of 3′ sialyllactose by B. bifidum PRL2010 
during an in vitro sequential co-culture experiment8. Similarly B. breve UCC2003 cannot directly utilise the most 
abundant HMO in mother’s milk, fucosyllactose (2′FL or 3′FL), but can crossfeed on monosaccharides, includ-
ing fucose, that are released during co-culture with B. bifidum PRL2010 in mMRS medium supplemented with 
porcine mucin9.
N-acetylglucosamine deacetylase (NagA) activity is central to the metabolism of HMOs and host derived 
carbohydrates, whereby NagA catalyses the conversion of N-acetylglucosamine 6-phosphate to glucosamine 
6-phosphate. The genome of B. breve UCC2003, ate, harbours 2 genes, namely Bbr_0846 and Bbr_1247 (des-
ignated nagA1 and nagA2, respectively) whose protein products, NagA1 and Nag A2, respectively, share 74% 
identity and are predicted to encode N-acetyl glucosamine deacetylase activity. Expression of nagA1is signifi-
cantly upregulated during growth of B. breve UCC2003 in mMRS medium supplemented with the host derived 
sulphated carbohydrate N-acetyl glucosamine-6-sulphate (GlcNAc-6-S) or Lactosamine-HCl, while expression 
of nagA2 is significantly upregulated during growth of B. breve UCC2003 in mMRS medium supplemented with 
sialic acid, LNT, LNnT, GlcNAc-6-S and also when B. breve UCC2003 is grown in co-culture with B. bifidum 
PRL2010 in medium supplemented with mucin8–11. Previously a B. breve UCC2003-nagA2 insertion mutant 
strain was found to exhibit growth comparable to that of the parent strain, B. breve UCC2003, in medium sup-
plemented with sialic acid as sole carbohydrate source suggesting that NagA1 may compensate in the absence of 
NagA2 activity8.
To extend our understanding of bifidobacterial mutualism and carbohydrate syntrophy in the gut we adopted 
advanced functional genomics to create single- and double-deletion isogenic strains of the NagA-encoding genes 
of B. breve UCC2003. The resulting strains were examined, as compared to the parent strain, for their ability 
to metabolise particular host-derived carbohydrates. In addition, the B. breve strains were examined for their 
cross-feeding capability and ability to establish, in the presence of B. bifidum, in the gut of dam fed neonatal mice.
Results
Phenotypic analysis of B. breve UCC2003 strains harbouring deletions of the N-acetyl glu-
cosamine deacetylase encoding genes, nagA1 and nagA2. To establish if N-acetyl glucosamine 
deacetylase activity is essential for the metabolism of sialic acid and other host derived carbohydrates 
isogenic B. breve UCC2003 derivative strains harbouring inframe deletions of nagA1 or nagA2, and a double 
(nagA1nagA2) deletion strain were created, and designated B. breve UCC2003ΔnagA1, UCC2003ΔnagA2 or 
UCC2003ΔnagA1ΔnagA2, respectively. These three mutants were compared to B. breve UCC2003 for their 
ability to utilise lactose, sialic acid, Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), or N-Acetyl-D-
glucosamine-6-O-sulfate (GlcNAc-6-S) as the sole carbohydrate source. All strains achieved final optical den-
sities (OD 600nm) greater than 2.0 in mMRS medium supplemented with lactose (positive control). In mMRS 
medium supplemented with sialic acid, LNT, LNnT or GlcNAc-6-S B. breve UCC2003, UCC2003ΔnagA1, 
UCC2003ΔnagA2 achieved comparable final optical density values for each carbohydrate substrate, while growth 
of B. breve UCC2003ΔnagA1ΔnagA2 was impaired (Fig. 1).
Carbohydrate syntrophy enhances the establishment of Bifidobacterium breve UCC2003 in the 
neonatal gut. In order to establish if the ability to metabolise host derived carbohydrates enhances the num-
bers of B. breve UCC2003 in the gastrointestinal tract of Dam-reared neonatal murine pups, a co-association 
study was performed. Groups of 7 pregnant C57BL/6 Germ free mice were administered a single dose of 1 × 109 
cfu of each B. bifidum PAM5 and B. breve UCC2003PK1, or B. bifidum PAM5 and UCC2003∆nagA1 + 2PK1. 
Fecal samples were collected weekly during the trial period to enumerate bifidobacterial shedding and determine 
the relative colonisation ability of B. bifidum PAM5, B. breve UCC2003PK1 or B. breve UCC2003∆nagA1 + 2PK1. 
Interestingly, despite administration at equal levels, B. breve UCC2003 or B. breve UCC2003∆nagA1 + 2PK1 col-
onised the pregnant mice at approximately 100 fold higher level as compared to B. bifidum PAM5 (Fig. 2a). This 
difference in colonisation ability between B. breve UCC2003 derivatives and B. bifidum PAM5 was also reflected 
Figure 1. Final optical densities (OD 600 nm) of B. breve UCC2003, UCC2003ΔnagA1, UCC2003ΔnagA2 
or UCC2003ΔnagA1ΔnagA2 following 24 hours growth in mMRS medium supplemented with lactose, sialic 
acid, LNT, LNnT or GlcNAc-6-S at 0.5% w/v final concentration.
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in the numbers of each strain recovered from the caecum and large intestine of the adult mice at the end of the 
trial period (Fig. 2b and c). The first litters of pups were born 9 days after administration of the Bifidobacterium 
strains, with all pups born within a period of 5 days. For Group A, administered B. bifidum PAM5 and B. breve 
UCC2003PK1, just three of the seven mothers produced litters of pups, while for Group B administered B. bifi-
dum PAM5 and B. breve UCC2003∆nagA1 + 2PK1 five of the seven mothers gave birth to litters of pups (Table 1). 
All pups were allowed to feed from their mothers and at 2 time points postpartum, and while the pups were 
exclusively dam reared, half of each group was culled for enumeration of each Bifidobacterium strain in the cae-
cum or large intestine based by plate counting with selection based on antibiotic resistance. For Group A, where 
Figure 2. Co-colonisation of B. breve UCC2003PK1 and B. bifidum PAM5 or B. breve UCC2003ΔnagA1 + 2′ 
PK1 and B. bifidum PAM5 in pregnant germ free C57BL/6 mice (a) Recovery of B. breve UCC2003PK1 (pale 
blue) and B. bifidum PAM5 (dark blue) or B. breve UCC2003ΔnagA1ΔnagA2 (orange) and B. bifidum PAM5 
(yellow) from murine fecal samples of C57BL/6 co-associated mice over 4 week trial period. (b) Comparison 
of numbers of B. breve UCC2003PK1 and B. bifidum PAM5 or (c) B. breve UCC2003ΔnagA + 2PK1 and B. 




of pups in 
litter
Cull day: 1 Cull day: 2
Number of pups  
(age in days)
Number of pups  
(age in days)
Group A: administered 
B. bifidum PAM5 and 
UCC2003PK1
A1 8 4 (10 days) 4 (14 days)
A2 0




A7 7 3 (11 days) 4 (15 days)
Total 9 animals Total 9 animals
Group B: administered 
B. bifidum PAM5 and 
UCC2003∆nagA1 + 2PK1
B1 5 2 (8 days) 3 (12 days)
B2 6 3 (12 days) 3 (16 days)
B3 8 4 (10 days) 4 (14 days)
B4 0
B5 7 3 (10 days) 4 (14 days)
B6 4 2 (9 days) 2 (13 days)
B7 0
Total 14 animals Total 16 animals
Table 1. Number of pups born to each C57Bl/6 mother and number of dam-reared pups culled at each timepoint.
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pregnant mothers were administered B. bifidum PAM5 and B. breve UCC2003PK1, mother-to-pup transmis-
sion of both Bifidobacterium strains was observed with B. breve UCC2003PK1 present at a level that was almost 
100-fold higher as compared to that achieved by B. bifidum PAM5 in the large intestine of the pups at each time 
point (p ≤ 0.001on cull day 1 and 2), achieving average levels of 1 × 106 cfu and 1.3 × 104 cfu, respectively, on cull 
day 1, while levels of 2.59 × 107 cfu and 6.3 × 105 cfu, respectively were recovered from the large intestine on cull 
day 2 (Fig. 3a and b). Similarly, for Group B, where mothers were administered B. bifidum PAM5 and B. breve 
UCC2003∆nagA1 + 2PK1, mother-to-pup transmission of both bifidobacterial strains was observed. However, 
the numbers of B. breve UCC2003∆nagA1 + 2PK1 and B. bifidum PAM5 were not significantly different on either 
cull day. Average levels of B. breve UCC2003∆nagA1 + 2PK1 and B. bifidum PAM5 recovered from the large 
intestines were 6.5 × 105 and 3.1 × 105 respectively, on the first cull day, with levels of each strain increasing to 
2.3 × 106 cfu and 1.77 × 106 cfu, respectively on cull day 2 (Fig. 3a and b).
B. breve UCC2003 or UCC2003∆nagA1 + 2 transcriptome during colonisation of dam-reared neonatal 
mice. To determine the B. breve UCC2003 or UCC2003∆nagA1 + 2 genes that are differentially transcribed in 
the gut of the dam-reared neonatal mice relative to the transcriptional profile under laboratory conditions, total 
bacterial RNA was isolated from the large intestines of neonatal mice harbouring B. breve UCC2003PK1 and B. 
bifidum PAM5 or B. breve UCC2003∆nagA1 + 2PK1 and B. bifidum PAM5. The RNA was reverse transcribed 
and the cDNA used to determine the in vivo transcriptome of each strain as compared to an exponential phase 
culture B. breve UCC2003 grown in mMRS supplemented with ribose. A total of 74 B. breve UCC2003 genes were 
significantly upregulated in vivo (≥3 fold; p < 0.001) and 95 downregulated (≥8 fold; p < 0.001), while for B. 
breve UCC2003∆nagA1 + 2PK1 23 genes were significantly upregulated in vivo (≥3 fold; p < 0.01) and 88 down-
regulated (≥8 fold; p < 0.001) relative to the control. The most highly upregulated genes were in loci dedicated to 
carbohydrate metabolism. In particular genes Bbr_1551 and Bbr_1552, dedicated to lactose transport and metab-
olism were significantly upregulated in both B. breve UCC2003PK1 and B. breve UCC2003∆nagA1 + 2PK1 under 
in vivo conditions, while genes in the sialic acid metabolism locus (Bbr_0160-Bbr_0172), the fucose metabolism 
locus (Bbr_1741–1745), and the nag and sulphatase locus (Bbr_0846- Bbr_0853) were significantly upregulated 
in B. breve UCC2003PK1 but not in B. breve UCC2003∆nagA1 + 2PK1 under in vivo conditions (Table 2). In 
addition, genes predicted to be remnants of an N-acetylglucosamine PTS system (Bbr_1878-Bbr_1880) were also 
upregulated in B. breve UCC2003PK1. Expression of the bile salt hydrolase encoding gene (BBr_1520) and several 
genes encoding hypothetical membrane proteins were upregulated in both B. breve UCC2003PK1 and B. breve 
UCC2003∆nagA1 + 2PK1under in vivo conditions indicating that B. breve UCC2003 expresses specific sets of 
genes in response to the in vivo environment and during feeding on mother’s milk (Table S1).
Discussion
The predominant carbohydrate in human milk is lactose which is found at a concentrations ranging from of 
60–70 g L−1. The concentration of HMOs, with a degree of polymerisation ≥3, in human milk varies consid-
erably, with values of 22–24 g L−1 in colostrum, and 12–13 g L−1 in mature milk12. HMOs comprise more than 
200 oligosaccharide structures that are classified as Type I or Type II oligosaccharides based the disaccharide 
lacto-N-biose or N-acetyllactosamine, respectively, at their reducing end. Fucosyllactose, Lacto-N-tetraose and 
Lacto-N-fucopentaose are the most abundant HMOs, and these 3 oligosaccharides can comprise up to 55% of the 
HMO content of human milk12–14. The predominance of Type I oligosaccharides is a feature of human milk, also 
found in mother’s milk of chimpanzees and elephants, however, among other mammals and marsupials Type II 
oligosaccharides tend to dominate15.
Figure 3. Enumeration of Bifidobacteria from the intestine of dam reared mice. Enumeration of B. breve 
UCC2003PK1 and B. bifidum PAM5 (shaded black), or B. breve UCC2003ΔnagA1 + 2PK1 and B. bifidum 
PAM5 (shaded grey) on cull day 1 (a) or 2 (b) from the intestine or caecum of dam reared neonatal mice.
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In this study we sought to establish the role of the B. breve N-acetylglucosamine deacetylases, NagA1 
and NagA2, in utilising host-derived carbohydrates including HMOs. In contrast to the parental strain, B. 
breve UCC2003, and the single deletion strains, B. breve UCC2003∆nagA1or UCC2003∆nagA2, B. breve 
UCC2003∆nagA1∆nagA2 was incapable of utilising sialic acid, LNT, LNnT or GlcNAc-6-S as sole carbohydrate 
source while this double nagA deletion strain exhibits growth comparable to the parent strain, and the single 
deletion strains, in medium supplemented with lactose.
We next wished to establish if the ability to metabolise host-derived oligosaccharides confers B. breve with 
a growth advantage in the neonatal gut. There has been a recent surge in publications describing the oligosac-
charide composition of mother’s milk from various animal sources, however despite laboratory mice being used 
extensively for research purposes, deciphering the oligosaccharide fraction of murine milk has received relatively 
little attention. This is likely due to the difficulty in obtaining sufficient volumes of milk for analysis. Despite 
this obstacle, Prieto et al.16 successfully determined the oligosaccharide composition of murine milk and estab-
lished that in addition to lactose, murine milk contains oligosaccharides including sialyllactose (3′SL and 6′SL) 
and fucosyllactose. Since B. breve UCC2003 does not directly utilise these milk oligosaccharides we adopted a 
co-inoculation strategy whereby two groups of 7 pregnant germ free mice were gnotobiotically co-colonised 
with B. breve UCC2003PK1 and B. bifidum PAM5 or B. breve UCC2003∆nagA1 + 2PK1 and B. bifidum PAM5. 
Interestingly, the B. breve strains colonised the pregnant adult mice at an approximately 2 log higher level as 
compared to B. bifidum PAM5. This is likely due to the ability of UCC2003 PK1 or UCC2003∆nagA1 + 2PK1 to 







Bbr_0160 Conserved hypothetical protein 2.80a —b
Bbr_0161 Conserved hypothetical protein in ROK family — —
Bbr_0162 N-acetylmannosamine-6-phosphate 2-epimerase 4.52 2.39
Bbr_0163 Hydrolase — —
Bbr_0164 Substrate binding protein 11.89 —
Bbr_0165 ABC transport system permease protein 5.36 —
Bbr_0166 ABC transport system ATP-binding protein 7.60 3.11
Bbr_0167 ABC transport system ATP-binding protein 7.57 —
Bbr_0168 nanA N-acetylneuraminate lyase 20.35 4.7
Bbr_0169 Glucosamine-6-phosphate isomerase 9.00 —
Bbr_0171 Sialidase A 4.49 —
Bbr_0172 ATPase — —
nag genes and metabolism of sulphated sugars
Bbr_0846 nagA1 N-acetylglucosamine-6-phosphate deacetylase 2.0 —
Bbr_0847 nagB2 Glucosamine-6-phosphate isomerase 3.78 —
Bbr_0851 Glucose/fructose transport protein 5.55 2.95
Bbr_0852 Sulfatase family protein 2.04 —
Bbr_0853 atsB Arylsulfatase regulator (Fe-S oxidoreductase) — —
Bbr_0854 Conserved hypothetical 2.12 —
Bbr_0855 Hypothetical protein 5.14 —
Lactose metabolism
Bbr_1550 Hypothetical protein 6.24 4.94
Bbr_1551 lacS Galactoside symporter 4.50 3.86
Bbr_1552 lacZ6 Beta-galactosidase 4.41 4.25
Fucose metabolism
Bbr_1741 Conserved hypothetical protein 4.91 —
Bbr_1742 L-fucose permease 3.16 —
Bbr_1743 Short chain dehydrogenase 3.35 —
Bbr_1744 Mandelate racemase 3.33 —
Bbr_1745 Transcriptional regulator — —
Remnants of Putative N-acetylglucosamine PTS system
Bbr_1878 Hypothetical protein 3.27 —
Bbr_1879 PTS system, glucose-specific IIABC component 6.15 —
Bbr_1880 PTS system, N-acetylglucosamine-specific IIBC component 6.77 3.78
Table 2. Differential expression of carbohydrate utilisation gene loci in B. breve UCC2003PK1 or B. breve 
UCC2003ΔnagA1ΔnagA2PK1 under in vivo conditions in dam-reared neonatal mice. aFold upregulation ≥2 
and p value ≤ 0.001. bValues below threshold.
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compared to B. bifidum PAM5 were also reflected in the bacterial numbers in the caecum and large intestine of 
the adult mice at the end of the trial period. Despite being housed in the same animal room and under the same 
conditions just 3 of the 7 mothers in group A produced viable litters, while 5 of the 7 mothers in group B produced 
viable litters. We attribute this relatively low number of mothers producing litters to the C57Bl/6 mice being first 
time mothers, and had we used established C57Bl/6 breeding mice more viable litters may have been obtained. 
Despite this, we obtained sufficient pups to have two timepoints for analysis while the pups were exclusively 
dam-reared. For each group of mice we observed mother-to-pup transmission of the Bifidobacterium strains. 
Enumeration of B. breve UCC2003PK1 and B. bifidum PAM5 from the caecum or large intestine of the pups on 
either cull day showed an almost 2 log higher level of B. breve UCC2003PK1 as compared to B. bifidum PAM5, 
while the numbers of B. breve UCC2003∆nagA1 + 2PK1 or B. bifidum PAM5 were not significantly different.
This data clearly indicates that the ability to cross-feed on host-derived carbohydrates provides B. breve 
UCC2003 with a competitive advantage, as compared to it’s isogenic double mutant or B. bifidum PAM5, that 
allows this strain to establish to a higher level in the gut of the dam-reared neonatal mice. To validate our findings 
we determined the in vivo transcriptome of B. breve UCC2003PK1 or UCC2003∆nagA1 + 2 as compared to 
UCC2003 grown under in vitro conditions. The in vivo transcriptome of both strains shows significant upreg-
ulation of genes involved in lactose metabolism demonstrating that both B. breve UCC2003PK1 or B. breve 
UCC2003∆nagA1 + 2PK1 are utilising lactose as a carbohydrate source in the neonatal gut. However, gene loci 
involved in metabolism of sialic acid, fucose and sulphated sugars were significantly upregulated in the in vivo 
transcriptome of B. breve UCC2003, yet not in that of B. breve UCC2003∆nagA1 + 2PK1, demonstrating that 
sialic acid, fucose and sulphated sugars are a valuable carbohydrate source, and metabolised by B. breve in the 
neonatal gut. Interestingly, transcription of the bile salt hydrolase-encoding gene was upregulated in both strains 
under these in vivo conditions, as well as a number of genes encoding uncharacterised membrane spanning hypo-
thetical protein, suggesting that they may mediate microbe-microbe, or microbe-host dialogue.
Collectively these data demonstrate that bifidobacterial mutualism and carbohydrate syntrophy occurs 
in the neonatal gut, thereby allowing B. breve strains that to not directly metabolise dominant host-derived 
oligosaccharides to efficiently cross-feed and achieve high numbers. In addition, these data suggest that the 
intracellular levels amino sugars N-acetylglucosamine and N-acetylgalactosamine or glucosamine 6-phosphate 
may be key intermediates regulating the expression of B. breve loci dedicated to metabolising host-derived 
oligosaccharides.
Methods
Bacterial strains, plasmids and culture conditions. Bacterial strains and plasmids used in this study 
are listed in Table 3. Bifidobacterial strains were routinely cultured in reinforced clostridial medium (RCM; Oxoid 
Ltd, Basingstoke, Hampshire, United Kingdom). Carbohydrate utilization by bifidobacteria was examined in de 
Man Rogosa and Sharpe Medium (MRS) prepared from first principles18. Prior to inoculation MRS was sup-
plemented with cysteine-HCl (0.05% w/v) and a particular carbohydrate source (0.5% w/v). The carbohydrates 
used were lactose and sialic acid (purchased from Sigma), N-Acetyl-D-glucosamine-6-O-sulfate (purchased from 
Dextra laboratories, Reading, UK), Lacto-N-tetraose (purchased from Elicityl, Crolles, France) and Lacto-N-
neotetraose (obtained from Glycom, Lyngby, Denmark). Bifidobacterial cultures were incubated at 37 °C under 
anaerobic conditions which were maintained using an anaerobic hood (Davidson and Hardy, Belfast, Ireland). 
Escherichia coli was cultured in Luria Bertani broth (LB)19 at 37 °C with agitation. Where appropriate growth 
media contained tetracycline (Tet; 15 μg ml−1), chloramphenicol (Cm; 5 μg ml−1 for E. coli or 2.5 μg ml−1 for 
B. breve), Spectinomycin (Spec; 100 μg ml−1 for E. coli or B. breve) or kanamycin (Km; 50 μg ml−1 for E. coli). 
Recombinant E. coli cells containing pBS423∆rep were selected on LB agar containing Spec.
Nucleotide sequence analysis. Sequence data were obtained from the Artemis-mediated20 genome anno-
tations of the B. breve UCC200321. Database searches were performed using non-redundant sequences accessible 
at the National Centre for Biotechnology Information internet site (http://www.ncbi.nlm.nih.gov) using Blast.
DNA manipulations. Chromosomal DNA was isolated from B. breve UCC2003 as previously described22. 
Minipreparation of plasmid DNA from E. coli or B. breve was achieved using the Qiaprep spin plasmid miniprep 
kit (Qiagen GmBH, Hilden, Germany). For B. breve an initial lysis step was included whereby cells are incubated 
in lysis buffer containing 30 mg ml−1 of lysozyme for 30 minutes at 37 °C. Single stranded oligonucleotide primers 
used in this study were synthesized by Eurofins (Ebersberg, Germany). Standard PCRs were performed using 
TaqPCR mastermix (Qiagen), while high fidelity PCR was achieved using Q5 DNA polymerase (New England 
Biolabs, Ipswich, MA, United States). B. breve colony PCRs were performed as described previously (O’Connell 
Motherway et al.17). PCR fragments were purified using the Roche high pure PCR purification kit (Roche, Hilden, 
Germany). Electroporation of plasmid DNA into E. coli was performed as described by Sambrook et al.19 and into 
B. breve UCC2003 as described by Maze et al.23.
Construction of B. breve UCC2003 deletion mutants. Isogenic non-polar deletion mutants of 
nagA1 (Bbr_0846), nagA2 (Bbr_1247) or a double deletion strain harbouring deletions in both nagA1 and 
nagA2, with 846 bp of the 1245 bp of nagA1, or 969 bp of the 1278 bp of nagA2 deleted, were created using 
pBS423Δrep constructs and generated by the splicing by overlap extension (SOEing) PCR procedure24. In 
each case primers SOE AB and SOE CD (Table 4) were used to amplify regions flanking the sequence to be 
deleted using genomic DNA of B. breve UCC2003 as template. The resulting products, designated I or II were 
purified, mixed in a 1:1 ratio and used as template with primers SOE EF. The resulting product was digested 
with Pst1 and ligated to similarly digested pBS423Δrep prior to transformation into E. coli EC101 by electro-
poration. Transformants were selected based on resistance to Km and Spec, and screened by colony PCR using 
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primers pBSF and pBSR to identify clones harbouring the correct insert. The presence of the correct insert in 
a number of positive clones was confirmed by plasmid isolation and restriction analysis, while the sequence 
integrity of the cloned DNA fragment and the orientation of the insert in the pBS423Δrep vector was con-
firmed by sequencing. First crossover insertion mutations were generated essentially as described previously25 
to produce B. breve UCC2003 derivatives that were designated UCC2003-nagA1-(I), UCC2003-nagA1-(II), 





   E. coli EC101 Cloning host, repA+ kmr 29
    E. coli EC101-pNZ-M.BbrII + M.BbrIII EC101 harbouring pNZ8048 derivative containing bbrIIM and bbrIIIM, Cmr 25
Bifidobacterium sp. strains
   B. breve UCC2003 Isolate from nursling stool 21
   B. breve UCC2003-nagA1-(I) UCC2003 pBS423Δrep first crossover integrant via nagA1 deletion fragment I, Specr This study
   B. breve UCC2003-nagA1-(II) UCC2003 pBS423Δrep first crossover integrant via nagA1 deletion fragment II, Specr This study
   B. breve UCC2003-nagA2-(I) UCC2003 pBS423Δrep first crossover integrant via nagA2 deletion fragment I, Specr This study
    B. breve UCC2003-nagA1-(I)-pRTB101 B. breve UCC2003-nagA1-(I) harbouring pRTB101, Specr, Cmr This study
    B. breve UCC2003-nagA1-(II)-
pRTB101 B. breve UCC2003-nagA1-(II) harbouring pRTB101 Spec
r, Cmr This study
    B. breve UCC2003-nagA2-(I)-pRTB101 B. breve UCC2003-nagA2-(I) harbouring pRTB101 Specr, Cmr This study
   B. breve UCC2003ΔnagA1 nagA1 846 bp inframe deletion mutant of UCC2003 This study
   B. breve UCC2003ΔnagA2 nagA2 969 bp inframe deletion mutant of UCC2003 This study
   B. breve UCC2003ΔnagA1ΔnagA2 nagA1, nagA2 double deletion mutant of UCC2003 This study
   UCC2003PK1 B. breve UCC2003 harbouring pPKCM Cmr 21
   UCC2003ΔnagA1 + 2PK1 B. breve UCC2003ΔnagA1ΔnagA2 harbouring pPKCM Cmr This study
   B. bifidum ATCC29521(PRL2010) B. bifidum type strain ATCC
   B. bifidum PAM5 B. bifidum ATCC29521 harbouring pAM5 Tetr This study
Plasmids
   pBS423Δrep 4.4 kb, E. coli- vector, ΔpMB1, ori pTB4 ori repA Specr 30
   pRTB101 7.3 kbp, E. coli-Bifidobacterium shuttle vector, pMB1 ori pTB4 ori repA 30
   pPKCM pCIBA089-pSK-Cmr 31
   pAM5 pBC1-puC19-Tetr 32
Table 3. Bacterial Strains and Plasmids used in this study. ATCC’ American type culture collection.
Purpose Primer Sequencea
























Table 4. Oligonucleotide Primers used in this Study. aRestriction sites incorporated into oligonucleotide primer 
sequences are indicated in bold.
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or UCC2003-nagA2-(I), respectively where I or II indicate that the first crossover occurred via fragment I or 
II (described above). Site-specific recombination in potential spec-resistant mutant isolates was confirmed 
by colony PCR using primer combinations specFw and specRv to verify Specr-encoding gene integration, 
and primers nagA1SOE A or nagA2SOE A (positioned upstream of the selected flanking regions of nagA1 
or nagA2 respectively), each in combination with pBSR or to confirm integration at the correct chromo-
somal location. To promote pBS423Δrep plasmid excision in UCC2003-nagA1-(I), UCC2003-nagA1-(II), 
or UCC2003-nagA2-(I) the incompatible plasmid pRTB101-CM was introduced into each strain and trans-
formants were selected on RCA supplemented with CM. CM resistant colonies were subcultured for eight 
transfers to promote loss of integrated pBS423Δrep. Cells which had excised pBS423Δrep and had either 
reverted to the wild type genotype, or harboured a nagA1 or nagA2 deletion, were selected based on Cmr Specs. 
Screening of Specs colonies for UCC2003 derivatives harbouring nagA1 or nagA2 deletion was performed by 
colony PCR using primer pairs nagA1SOEA and nagA1SOEB or nagA2SOEA and nagA2SOEB, respectively, 
and sequencing of the PCR products to confirm the inframe deletion. Curing of pRTB101-CM from B. breve 
deletion mutant strains was performed by subculturing at 42 °C for 8 transfers followed by plating on RCA 
and screening for CM sensitive mutant strains by replica plating. Construction of the double deletion strain B. 
breve UCC2003ΔnagA1ΔnagA2 was performed sequentially whereby the deletion strain UCC2003ΔnagA2 
was constructed first and this strain was used as host for construction of a deletion of nagA1.
Mother-to-pup transmission of B. bifidum and B. breve. All experiments using mice were approved 
by the University College Cork animal ethics committee and all methods were performed in accordance with 
the relevant guidelines and regulations. Twelve-week-old pregnant female, germ-free C57BL/6 mice were 
housed in flexible film gnotobiotic isolators under a strict 12 h light cycle. Mice were fed an autoclaved standard 
polysaccharide-rich mouse chow diet. At approximately 11 days of gestation two groups of mice (n = 7 per group) 
were inoculated with 1 × 109 cfu of B. bifidum PAM5 and B. breve UCC2003PK1, or B. bifidum PAM5 and B. breve 
UCC2003∆nagA1 + 2PK1 in 20 μl of PBS by oral pipetting whereby the inoculums are delivered by positioning a 
micropipette tip immediately behind the incisors. Five mice were maintained as uninoculated controls to monitor 
the germ free status of the facility. Fecal pellets were collected weekly to determine the density of bacterial colo-
nisation of each strain based on colony forming units. At approximately 9 days after inoculation the first litter of 
pups was born and all litters were born within the following 5 days. Half of each dam-reared litter was sacrificed 
at each of two time points, while the mice were exclusively dam-fed, the first timepoint was at postnatal day 8–11, 
with the second four days later when mice aged between 12 and 16 days (Table 1). The stomachs of all culled pups 
were inspected to ensure no chow particles were present. Enumeration of bifidobacterial strains in the caecum 
and large intestine of each pup was performed using antibiotic selection and plate counting. Enumeration of the 
bifidobacterial strains in the caecum and large intestine of each mother was also determined at the end of the trial 
period.
Statistical analysis. Results are presented as mean +/− SEM. Findings were statistically evaluated using 
one-way Anova with Dunnett’s post-test. The p value, p < 0.0001, p < 0.001 or p < 0.01 is indicated by three, two 
or one stars (*), respectively as appropriate. ns indicates non-significant.
Transcriptional profiling of B. breve UCC2003 and UCC2003∆nagA1 + 2PK1. Large intestine 
samples from each group of neonatal pups were snap frozen in liquid nitrogen. After thawing in RNA protect 
solution each tissue sample was homogenised to separate the luminal contents from the mucosa, and centri-
fuged (1,200 × g for 10 sec) to remove the tissue fragments. The resulting bacterial supernatants were subjected 
to bacterial cell lysis and RNA isolation as described previously21,26. cDNA from bacterial mRNA was synthe-
sized using the cDNA synthesis and labelling kit DSK-001 (Kreatech, Amsterdam, Netherlands) according to 
the manufacturer’s instructions and labelled with Cy3 or Cy5 using Cy3-ULS and Cy5-ULS from the cDNA 
synthesis and labelling kit DSK-001 (Kreatech). DNA-microarrays containing oligonucleotide primers represent-
ing each of the 1864 annotated genes on the genome of B. breve UCC2003 were designed by and obtained from 
Agilent Technologies (Palo Alto, Ca., USA). Labelled and amplified cDNA was hybridized using the Agilent Gene 
Expression hybridization kit (part number 5188–5242) as described in the Agilent Two-Color Microarray-Based 
Gene Expression Analysis (v4.0) manual (publication number G4140–90050). Notably, we do not see cross 
hybridisation of B. bifidum cDNA with the B. breve oligos on these arrays9. Following hybridization, microar-
rays were washed were washed in accordance with Agilent’s standard procedures and scanned using an Agilent 
DNA microarray scanner (model G2565A). Generated scans were converted to data files with Agilent’s Feature 
Extraction software (Version 9.5). DNA-microarray data were processed as previously described27. Differential 
expression tests were performed with the Cyber-T implementation of a variant of the t-test28. A gene was consid-
ered differentially expressed when p < 0.001 and an expression ratio of >2 or <0.33 relative to the control. The 
microarray data have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series 
accession number GSE110077.
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